Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group (Q34546186)
scientific article
Language:
(P31) (Q13442814)
(P50) (Q66809340)
(Q56722240)
(P304) 689-695
(P407) (Q1860)
(P433) 5
(P478) 40
(P577) Monday, March 1, 2004
(P921) (Q181600)
(Q1955810)
(Q177094)
(P1433) (Q332260)
(P1476) "Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group" (language: en)
(P2093) H Dumez
I Judson
J Verweij
M Brown
S Dimitrijevic
R Sciot
M Stul
H Vranck
M Scurr
A Hagemeijer
M van Glabbeke
A T van Oosterom
EORTC Soft Tissue and Bone Sarcoma Group
other details
description scientific article

External Links